Drug Search Results
More Filters [+]

Palazestrant

Alternative Names: Palazestrant, op-1250, op1250, op 1250
Latest Update: 2024-07-02
Latest Update Note: News Article

Product Description

OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen receptor.

Mechanisms of Action: ER Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Breast Cancer|Oncology Solid Tumor Unspecified *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Olema Pharmaceuticals
Company Location: SAN FRANCISCO CA 94107
Company CEO: Sean Bohen
Additonal Commercial Interests: Aurigene Discovery Technologies

Clinical Description

Map of Global Clinical Trials for Palazestrant

Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Korea, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Spain, Taiwan, Thailand, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OP-1250-301

P3

Recruiting

Breast Cancer

2027-11-30

OPERA-01

P3

Recruiting

Breast Cancer

2026-06-30

40%

OP-1250-002

P1

Active, not recruiting

Breast Cancer

2025-01-01

44%

OP-1250-001

P2

Active, not recruiting

Breast Cancer

2024-06-01

57%

Recent News Events